Clenbuterol pills 0.02 mg N50
Condition: New product
997 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Clenbuterol
Release form
Pills
Composition
Clenbuterol hydrochloride 0.02 mg Excipients: lactose monohydrate 70 mg, wheat starch 31.48 mg, microcrystalline cellulose 48.5 mg, colloidal silicon dioxide 2 mg, magnesium stearate 2 mg, povidone (povidone K25) 6 mg.
Pharmacological effect
Bronchodilator, is a stimulant of 2-adrenergic receptors of prolonged action. Bronchodilatory effect due to a direct relaxing effect on the muscles of the bronchi. May increase heart rate somewhat. It also has a tocolytic effect.
Pharmacokinetics
It has a high degree of absorption. High concentrations are created in plasma 15 minutes after a single dose and persist for 7-24 hours. It is eliminated mainly by the kidneys. T1 / 2 - 3 h.
Indications
Prevention and relief of bronchospasm in bronchial asthma; bronchitis with broncho-obstructive syndrome.
Contraindications
Thyrotoxicosis, tachycardia, tachyarrhythmia, subaortic aortic stenosis, acute period of myocardial infarction, pregnancy, hypersensitivity to clenbuterol.
Use during pregnancy and lactation
Contraindicated for use in pregnancy.
Dosage and administration
Is taken orally at a dose of 2.5-20 mg 2 times / day. The dose is set depending on the age of the patient and the clinical situation.
Side effects
Since the cardiovascular system: tachycardia, extrasystole, lowering blood pressure. From the side of the central nervous system: trembling fingers, anxiety, headache. On the part of the digestive system: dry mouth, nausea. Allergic reactions: the appearance of a skin rash. Other: hypokalemia.
Overdose
Symptoms: arrhythmia, tachycardia, arterial hypertension, cardialgia, tremor of the extremities, possible development of hypokalemia. Treatment: gastric lavage, the appointment of activated carbon, the use of water-salt solutions, control of serum potassium levels, symptomatic therapy.
Interaction with other drugs
Beta-blockers are pharmacological antagonists of clenbuterol and can eliminate its effect. Clenbuterol reduces the effects of hypoglycemic agents. Increases the risk of developing intracardiac conduction disorders, while the appointment with MAO inhibitors and theophylline.Increases the toxicity of cardiac glycosides and increases the risk of arrhythmias. In combination with sympathomimetic agents, a mutual increase in toxicity occurs.
special instructions
Development of resistance and rebound syndrome is possible. Do not allow contact with the drug in the eyes, especially with glaucoma.